UK company Cambridge Consultants is to license a range of technology development tools aimed at accelerating the creation of new inhalable drug delivery devices.
The company's Gen-X series of technologies, from de-agglomeration for fine particle doses (FPD) to drug storage chamber piercing and evacuation techniques, draw on the scientific and engineering expertise acquired through the development of more than 16 respiratory delivery devices over the past 15 years.
The group of core Gen-X technologies being licensed by Cambridge Consultants include the technology to accurately pierce a foil blister, evacuate the blister in a repeatable manner, and drug de-agglomerate technologies to provide tailored device performance. These, coupled with Cambridge Consultants" expertise in the development of solutions to technical challenges such as dose indexing and human factors, are said to provide a quick development path for new DPIs.
"In an industry where the time-to-market for inhalable dry powder drug delivery devices is often seven to 10 years, fast-tracking development with our proven Gen-X development platform can significantly reduce this timescale and the overall development risk," said Marek Myszko, business development manager, drug delivery at Cambridge Consultants.
